Related Experiment Video
Updated: Nov 22, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
11.5K
Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience.
Maria Eduarda Couto1, Isabel Oliveira1, Nelson Domingues1
1Department of Onco-hematology, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal.
Summary
This study shows that gastric diffuse large B cell lymphoma (DLBCL) is treatable with R-CHOP-like therapy, offering long-term survival. Key negative survival factors include older age and advanced disease stages.
Area of Science:
- Oncology
- Hematology
- Clinical Medicine
Background:
- Gastric diffuse large B cell lymphoma (DLBCL) is the most common type of gastric lymphoma.
- Understanding treatment outcomes and survival is crucial for managing this condition.
Purpose of the Study:
- To retrospectively analyze demographic features, treatment outcomes, and survival rates of gastric DLBCL patients.
- To identify prognostic factors influencing survival in gastric DLBCL.
Main Methods:
- Retrospective analysis of 101 gastric DLBCL patients treated between 2010 and 2018.
- Evaluation of Lugano staging, Helicobacter pylori infection, R-CHOP-like therapy, and response rates.
- Assessment of survival outcomes including overall survival and progression-free survival.
Main Results:
- A complete response rate of 80% was observed after first-line R-CHOP-like therapy.
- At 3-year follow-up, 54% of patients remained in complete remission.
- Factors negatively impacting survival included age >65, ECOG 2-3, B symptoms, bulky disease, IPI 3-4, multiple treatment lines, and lack of first-line response.
Conclusions:
- Gastric DLBCL is a potentially curable malignancy with R-CHOP-like therapy.
- The treatment offers favorable long-term survival comparable to other published series.
- Identifying negative prognostic factors can guide treatment strategies and patient management.
